# Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout

> **NCT07752810** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hangzhou Grand Biologic Pharmaceutical, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Phase 1b: HZBio1 3mg
- **DRUG:** Phase 1b: HZBio1 6mg
- **DRUG:** Phase 1b: HZBio1 12mg
- **DRUG:** Phase 2: HZBio1 6mg
- **DRUG:** Phase 2: HZBio1 9mg
- **DRUG:** Phase 2: HZBio1 12mg

## Key facts

- **NCT ID:** NCT07752810
- **Lead sponsor:** Hangzhou Grand Biologic Pharmaceutical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-23
- **Primary completion:** 2024-12-06
- **Final completion:** 2025-05-19
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752810, "Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07752810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*